UROTHELIAL CARCINOMA RECURRENT
Clinical trials for UROTHELIAL CARCINOMA RECURRENT explained in plain language.
Never miss a new study
Get alerted when new UROTHELIAL CARCINOMA RECURRENT trials appear
Sign up with your email to follow new studies for UROTHELIAL CARCINOMA RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New bladder cancer drug aims to match gold standard in major trial
Disease control Recruiting nowThis Phase 3 trial tests a new treatment called VERITY-BCG for people with intermediate or high-risk non-muscle invasive bladder cancer who have not received BCG therapy before. The study compares VERITY-BCG to the standard BCG treatment (OncoTICE) to see if it works just as well…
Matched conditions: UROTHELIAL CARCINOMA RECURRENT
Phase: PHASE3 • Sponsor: Verity Pharmaceuticals Inc. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for advanced bladder cancer: targeted drug combo enters phase 2 trial
Disease control Recruiting nowThis study tests a new drug (trastuzumab rezetecan) alone or with an immunotherapy (adebrelimab) in 96 adults with advanced or metastatic bladder cancer that has the HER2 protein. The goal is to see if the treatment shrinks tumors and how long it keeps the cancer from growing. Pa…
Matched conditions: UROTHELIAL CARCINOMA RECURRENT
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 04, 2026 16:22 UTC